Summary The use of different expressions of mortality in prostate cancer can lead to difficulty in comparing reported data. We have used different measures of mortality in the same group of 438 patients presenting consecutively with histologically proven adenocarcinoma of the prostate, in order to assess the values and deficiencies of each method. The use of expected and relative survival is shown to be valuable in allowing indirect but objective assessment of disease specific mortality in prostatic cancer.
Prostatic cancer presents at an age when concurrent disease is common, and therefore the interpretation of survival data in men with this disease is complicated by the need to take some account of age-related general mortality. Surprisingly, many reports considering aspects of survival in this disease fail to give adequate, if any, details of the age structure of the group of patients being reported (Parker et al., 1985; Merrick et al., 1985; Paulson & Walther, 1989) .
The problem of expressing disease specific mortality in prostate cancer has been addressed by a number of workers and different approaches have been used. While some authors have used relative survival (the ratio of observed to expected survival at a given time) to express disease specific mortality (Wilson et al., 1984; Johansson et al., 1989) , others (George, 1988) present survival curves of 'objective' and 'possible' deaths due to prostate cancer, by excluding 'noncancer deaths' on the basis of hospital records. Some report deaths due to 'unrelated causes', but do not define the methods used to ascertain cause of death (Parker et al., 1985) . Figure 5 with expected rates and overall death rate for comparison. Since patients were assessed in a specific prostate cancer clinic until shortly before death, data available from the pre-death visits were assessed to try to identify patients with signs of systemically progressive disease that might be considered likely to have led to death. Forty-six patients had rapidly rising acid phosphatase (defined here as increasing by a factor of > 1.8, within the abnormal range, twice in the 6 months up to pre-death visit) or alkaline phosphatase (defined as increasing during the 6 months up to pre-death visit by a factor of > 1.5, final value > 3 times upper limit of normal), or both, in the 6 months before the pre-death visit (Figure 6 ). These definitions are accepted as being essentially arbitrary, but the limits used appeared most effectively Months before death Figure 6 Serum alkaline (a) and acid (b) As may be expected, the certified cause of death is, at best, a crude measure of disease specific mortality and it would seem that most authors are correct in avoiding the use of death certification when reporting survival. There were a number of major discrepancies identified in this study. In 10 patients (4% of those dying) clinic data suggested neither advanced nor progressive disease, and yet prostate cancer was given as the cause of death on the death certificate, while in 37% of those dying, prostate cancer was not mentioned on any part of the death certificate. In this series the death certificate was most often completed by the patient's general practitioner (who is regularly informed of his patient's progress from the prostate clinic) and so the degree of consistency in death certification data might be expected to be even lower in regions not having a dedicated prostate cancer follow-up clinic.
Despite these inconsistencies, the 'cancer specific' probability of survival at 5 years calculated from the certification data is 51.1% (Figure 5 ), closely matching the relative survival rate at 5 years of 50.5%. Published national mortality rates (based on certification data) have in recent years remained close to 50% of the rate of new registrations of prostate cancer (Wilson, 1987) In conclusion, the interpretation of reports of survival in prostate cancer would be facilitated by the reporting of the expected survival (calculated in a clearly defined manner on the best available population data) of each group considered. This single statistic takes into account the age of each individual in the group and best describes the age related general mortality in the group. It can be compared directly between reports from different centres, allowing the reader to judge how much any difference in observed mortality is due to prostate cancer and its treatment, and how much is due to difference in general mortality. Relative survival at a given time can be easily computed and used as an indirect but objective expression of cancer specific mortality.
The reporting of cancer specific mortality based on using retrospective records to identify 'cancer deaths' and 'deaths due to other causes' is of limited value, since the criteria used cannot be simply defined in a reproducible manner. Death certification data are confirmed to be inaccurate in the context of prostate cancer mortality studies and should continue to be avoided. Reports of mortality and survival which fail to give any information on patient age cannot be interpreted sensibly.
